Clinicians at Duke University Hospital are some of the first to implant a bioengineered blood vessel into a human patient. The vein was developed by Duke spinoff Humacyte. The surgery is part of a larger phase 1 clinical trial on 20 patients with end-stage renal disease that Duke researchers are spearheading. The vessels are being implanted into the arms of the subjects to help with performing hemodialysis, and the researchers will be closely following up to analyze the safety and durability of the new grafts.
Current options have drawbacks. Synthetic vascular grafts are prone to clotting, leading to frequent hospitalizations, and harvesting veins from the patient’s own body involves a separate procedure, with the risk of infection and other complications.
If the bioengineered veins prove beneficial for hemodialysis patients, the researchers ultimately aim to develop a readily available and durable graft for heart bypass surgeries, which are performed on nearly 400,000 people in the United States a year, and to treat blocked blood vessels in the limbs.
The full article is located at Med Gadget